![]() ![]() Innovative products, such as Optimer-Fc, are actively being sought to overcome these issues.Īptamer is working with one of the top three companies within the IHC market (that jointly command over 70% of the market) to validate the performance of Optimer-Fc within their automated IHC platform and is in current negotiations with two top 10 pharmaceutical companies seeking to trial Optimer-Fc. However, the imminent expiry of current patents for IHC antibodies is a significant challenge facing the major players in this field, with an expected decrease in revenue and profitability. The IHC market was valued at $2.3BN in 2021, with 45.5% accounted for by the antibody segment. ![]() IHC remains the gold standard test for clinical diagnostics (including cancer), and its use is increasing with the advent of personalised medicine approaches. Capitalising on the highly selective and tuneable nature of Optimer binders, this development will enable life scientists to pursue novel and existing disease biomarkers and offer increased accuracy and selectivity in detection, with the generation of a suite of new reagents to enable improved research, diagnostics, and forensics. The Optimer-Fc is an antibody alternative for use within existing workflows replacing the primary, detecting, antibody. IHC is used to detect if cells have cancer or other disease markers. IHC is a staining process predominantly done on fresh or frozen clinical tissue samples removed during a biopsy. ![]() This allows the broad target range of Optimer tools to be applied in IHC applications. The Company has successfully demonstrated the functional integration of different Optimer binders into this conjugate format. Optimer-Fc tools consist of an Optimer binder conjugated to the Fc domain of an antibody. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |